[The activity of the neurohumoral regulatory systems, the status of the electrolyte balance and the clinical efficacy of Renitec in hypertension patients]. / Aktivnost' nekotorykh sistem neirogumoral'noi reguliatsii, sostoianie élektrolitnogo balansa i klinicheskaia éffektivnost' reniteka u bol'nykh gipertonicheskoi bolezn'iu.

Hypotensive effect of renitek (enalapril maleate) was assessed by activity of some neuroregulation systems and electrolyte balance in 16 patients with essential hypertension (EH). Maximal time of treatment for the assessment was 14 days. Renitek in a single dose 20-40 mg/day produced a response in 80% of EH stage II patients with low activity of plasma renin (PR). A hypotensive effect of the drug proved more essential in patients with higher baseline urinary excretion of aldosterone, adrenaline, noradrenaline and sodium. This effect is associated with stimulation of PR activity, urinary excretion of sodium, reduction in plasma and 24-h urine of aldosterone, adrenaline and noradrenaline concentrations. Renitek nonresponders exhibited high aldosterone concentration in plasma and its normal excretion with urine, diminished sodium excretion with urine. After 2 weeks of treatment blood and urine hormones were close to the initial levels while sodium excretion with urine went down.

[The antihypertensive activity of benazepril in the long-term treatment of hypertension patients and its effect on adrenal cortical function]. / Antigipertenzivnaia aktivnost' benazeprila pri dolgosrochnom lechenii bol'nykh gipertonicheskoi bolezn'iu i vliianie ego na funktsiiu kory nadpochechnikov.

Changes in arterial hypertension, heart rate and adrenocortical hormones (11-OCS, aldosteron, progestins) in the blood and 24-h urine were followed up in the course of 24-week use of angiotensin-converting enzyme inhibitor benazepril (10-20 mg once a day) in 24 patients with mild and moderate essential hypertension (EH) included in a placebo-controlled randomized study. A 2 and 24-week antihypertensive response was achieved in 75 and 71% of patients, respectively. 24-h urinary excretion of corticosteroids before the treatment was increased. After the treatment benazepril reduced excretion of 11-OCS by 42%, but not of aldosteron the levels of which decreased only within the first 2 weeks of treatment. The above trends in changes of gluco- and mineralocorticoid activity should be taken into consideration in long-term treatment of EH with inhibitors of angiotensin-converting enzyme.